MicroPort CardioFlow Medtech Corp. (2160) AI Stock Analysis

• Market Cap: HK$2.22B
• Dividend Yield: N/A
• Average Volume (3M): 6.63M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: 5.32%
• EPS Growth: 89.43%
• Country: HK
• Employees: 430
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): <0.01
• Shares Outstanding: 2,412,592,800
• 10 Day Avg. Volume: 5,393,400
• 30 Day Avg. Volume: 6,625,461
• PEG Ratio: -0.47
• Price to Book (P/B): 0.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: HK$1.00 ▲(5.26%Upside)

MicroPort CardioFlow Medtech Corp. has a strong equity base and promising revenue growth, which are positive indicators. However, significant profitability and cash flow challenges, along with a negative P/E ratio, weigh heavily on the overall score. The technical analysis suggests potential for short-term recovery, but long-term financial improvements are necessary for a stronger outlook.

MicroPort CardioFlow Medtech Corp. Business Overview & Revenue Model

Company Description

MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.

How the Company Makes Money

MicroPort CardioFlow Medtech Corp. generates revenue through the sale of its cardiovascular medical devices, particularly those used in minimally invasive procedures such as TAVI systems. The company's revenue streams include direct sales to hospitals and healthcare facilities, as well as partnerships and distribution agreements with medical device distributors and healthcare providers. The company invests in research and development to continuously innovate and expand its product offerings, which helps maintain competitive advantage and meet the growing demand for advanced cardiovascular treatments. Strategic partnerships and collaborations with healthcare institutions and research organizations also play a significant role in the company's revenue generation and market expansion efforts.

MicroPort CardioFlow Medtech Corp. Financial Statement Overview

Summary

MicroPort CardioFlow Medtech Corp. has strong revenue growth and a solid equity base, but faces significant challenges with profitability and cash flow. The negative EBIT, net income, and cash flow management issues indicate ongoing operational inefficiencies. The balance sheet strength is a positive factor but is outweighed by persistent losses.

Income Statement

MicroPort CardioFlow Medtech Corp. has shown substantial revenue growth over the years, with a revenue growth rate of 7.54% from 2023 to 2024. However, the company is struggling with profitability as indicated by negative EBIT and net income, resulting in negative EBIT and net profit margins. The gross profit margin improved slightly, showing a focus on cost management, but overall profitability remains a challenge.

Balance Sheet

The company's balance sheet is relatively strong with a high equity ratio of 81.74%, indicating a solid capital base. The debt-to-equity ratio is low at 0.04, reflecting minimal leverage and reduced financial risk. However, the return on equity remains negative, driven by sustained net losses, which undermines the overall financial health.

Cash Flow

The cash flow statement indicates significant operational challenges, with zero operating and free cash flow in the latest period. The absence of positive cash flows highlights ongoing operational inefficiencies. The company has shown improvements in reducing free cash flow deficits over the years, but cash flow management remains an area of concern.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	361.56M	336.21M	251.03M	200.81M	103.93M
Gross Profit	251.21M	229.93M	162.13M	118.70M	45.38M
EBITDA	-113.32M	-386.05M	-347.91M	-126.43M	-227.43M
Net Income	-49.45M	-471.53M	-454.39M	-183.26M	-608.98M
Balance Sheet
Total Assets	2.68B	2.58B	3.00B	3.36B	1.11B
Cash, Cash Equivalents and Short-Term Investments	1.36B	1.07B	1.87B	2.21B	612.47M
Total Debt	76.86M	70.48M	95.47M	125.64M	15.83M
Total Liabilities	454.07M	242.25M	247.55M	265.52M	1.46B
Stockholders Equity	2.19B	2.33B	2.75B	3.10B	-345.18M
Cash Flow
Free Cash Flow	-270.06M	-237.50M	-231.60M	-269.94M	-167.97M
Operating Cash Flow	-111.67M	-206.99M	-182.53M	-161.50M	-109.75M
Investing Cash Flow	-798.50M	-596.06M	-179.78M	-437.48M	-56.42M
Financing Cash Flow	-56.31M	-25.61M	-136.42M	2.23B	676.42M

MicroPort CardioFlow Medtech Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2160, the sentiment is Positive. The current price of 0.95 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 0.89, and above the 200-day MA of 0.83, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 71.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2160.

MicroPort CardioFlow Medtech Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2160	47 Neutral	HK$2.22B	―	-2.19%	―	5.32%	89.43%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%
4WO		€500.81M	―	-10.43%	―	―	―
1789	75 Outperform	HK$6.78B	22.73	10.92%	1.19%	20.19%	45.54%
1858	65 Neutral	HK$7.09B	35.93	4.39%	0.82%	-32.05%	-54.47%
2500	50 Neutral	HK$1.13B	―	-27.82%	―	-6.12%	0.43%
2393	47 Neutral	HK$286.54M	0.29	1417.08%	―	-20.01%	―

MicroPort CardioFlow Medtech Corp. Corporate Events

MicroPort CardioFlow Announces AGM Results and Board Changes

MicroPort CardioFlow Medtech Corp. announced the results of its Annual General Meeting held on June 27, 2025, where all proposed resolutions were approved by shareholders. The meeting also marked the retirement of an independent non-executive director and the appointment of a new one, leading to changes in the composition of the board committees. These developments are expected to influence the company’s governance and strategic direction, potentially impacting its market position and stakeholder relationships.

MicroPort CardioFlow Announces Board Composition and Roles

MicroPort CardioFlow Medtech Corp. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement is significant for stakeholders as it outlines the leadership structure, which can influence the company’s strategic direction and governance.

MicroPort CardioFlow Announces 2025 Annual General Meeting

MicroPort CardioFlow Medtech Corporation has announced its upcoming Annual General Meeting scheduled for June 27, 2025, in Shanghai, China. The meeting will address several key resolutions, including the approval for the directors to repurchase shares and to issue additional shares or securities. These resolutions, if passed, could impact the company’s capital structure and shareholder value, reflecting strategic moves to enhance market positioning and operational flexibility.

MicroPort CardioFlow Acquires Full Ownership of MP CardioAdvent

MicroPort CardioFlow Medtech Corp. has announced its acquisition of the remaining 49% equity interest in MP CardioAdvent, making it a wholly-owned subsidiary. This move is part of a strategic effort to consolidate its holdings and strengthen its position in the cardiovascular device market. The acquisition is classified as a disclosable and connected transaction under Hong Kong’s Listing Rules, requiring approval from independent shareholders.